Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous Close | 1.0900 |
| Open | 0.9900 |
| Bid | 0.0000 x 42300 |
| Ask | 0.0000 x 40000 |
| Day's Range | 0.9901 - 1.1006 |
| 52 Week Range | 0.8400 - 7.1500 |
| Volume | |
| Avg. Volume | 1,821,091 |
| Market Cap | 127.89M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1740 |
| Earnings Date | Aug 11, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.75 |
- GlobeNewswire
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations. “As Atossa continue
- GlobeNewswire
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is be
- Simply Wall St.
Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
